Gallieni Maurizio, Matoussevitch Vladimir, Steinke Tobias, Ebner Adrian, Brunkwall Silke, Cariati Maurizio, Gallo Santiago, Reindl-Schwaighofer Roman, Sengölge Gürkan
Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.
Department of Vascular Surgery, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany.
J Vasc Interv Radiol. 2020 Oct;31(10):1654-1660.e1. doi: 10.1016/j.jvir.2020.06.020. Epub 2020 Jul 8.
To report the device performance and safety for the Surfacer Inside-Out access catheter system in patients with thoracic central venous obstruction (TCVO) requiring central venous access (CVA).
Five sites prospectively enrolled 30 patients requiring a tunneled dialysis catheter between February 2017 and September 2018 in the SAVE (Surfacer System to Facilitate Access in Venous Obstructions) registry. Patient demographics, medical history, and type of TCVO were documented at enrollment. Device performance and adverse events were collected during the procedure and upon hospital discharge. Twenty-nine of the 30 patients enrolled required CVA for hemodialysis. Retrospective classification of TCVOs according to SIR reporting standards showed 9 patients (30%) had Type 4 obstructions, 8 (26.7%) had Type 3, 5 (16.7%) had Type 2, and 8 (26.7%) had Type 1 obstruction.
Central venous catheters (CVCs) were successfully placed in 29 of 30 patients (96.7%). The procedure was discontinued in 1 patient due to vascular anatomical tortuosity. All 29 patients with successful CVC placement achieved adequate catheter patency and tip positioning. There were no device-related adverse events, catheter malposition, or intra- or postprocedural complications. Mean time from device insertion to removal for the 29 patients who successfully completed the procedure was 24 ± 14.9 (range, 6-70) minutes. Mean fluoroscopy time was 6.8 ± 4.5 (range, 2.2-25.5) minutes.
The Surfacer Inside-Out procedure provided an alternative option to restore right-sided CVA in patients with TCVO.
报告用于有胸段中心静脉阻塞(TCVO)且需要中心静脉通路(CVA)的患者的Surfacer由内向外入路导管系统的设备性能及安全性。
在2017年2月至2018年9月期间,5个研究点前瞻性纳入了30例需要置入隧道式透析导管的患者,纳入SAVE(促进静脉阻塞时通路建立的Surfacer系统)登记研究。在入组时记录患者的人口统计学资料、病史及TCVO类型。在操作过程中及出院时收集设备性能及不良事件。30例入组患者中有29例因血液透析需要CVA。根据SIR报告标准对TCVO进行回顾性分类显示,9例(30%)为4型阻塞,8例(26.7%)为3型,5例(16.7%)为2型,8例(26.7%)为1型阻塞。
30例患者中有29例(96.7%)成功置入中心静脉导管(CVC)。1例患者因血管解剖结构迂曲而终止操作。所有29例成功置入CVC的患者导管通畅且尖端位置合适。未发生与设备相关的不良事件、导管位置不当或操作中及操作后的并发症。成功完成操作的29例患者从设备置入到拔除的平均时间为24±14.9(范围6 - 70)分钟。平均透视时间为6.8±4.5(范围2.2 - 25.5)分钟。
Surfacer由内向外入路操作法为TCVO患者恢复右侧CVA提供了一种替代选择。